Market Research Logo

PharmSource - Bio/Pharma CapEx Trends 2016

Executive Summary
Introduction
CapEx Overview
CapEx Relative to Other Financial Indicators
Nature of Capital Expenditure - What Is Being Built
What It Means
Appendix
Recently Announced and Completed Investments by Global Bio/Pharma Companies
Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies
Selected CapEx Investments by Generic Companies 2014 Onwards
List of Tables
Table 1 Composition of the PharmSource Universe
Table 2 Analysis of Identified CapEx Projects
Table 3 Location of Identified CapEx Projects
List of Figures
Figure 1 CapEx by Company Sector
Figure 2 Comparison of CapEx Change to Revenue Change 2010-
Figure 3 CapEx Trends at Bio/Pharma Companies 2010-
Figure 4 CapEx Spend and Growth Rate for Global Bio/Pharma Companies
Figure 5 Cash Spent on Dividends, Share Repurchase and CapEx by Selected US Global Bio/Pharma Companies 2010-
Figure 6 Capital Expenditure for Leading Public CDMOs

PharmSource - Bio/Pharma CapEx Trends 2016

Summary

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”

According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Scope

  • Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
  • It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
  • It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.
Reasons to buy
  • The 16-page report provides important insight that you won’t find in any other source. This report is required reading for -
  • CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
  • Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;